SCHEMBL16868359

SCHEMBL16868359

CCc1cc(NS(=O)(=O)CC)ccc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.53
HPGD P15428 7/20 0.50
LMNA P02545 3/20 0.50
HTT P42858 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
EPHX2 P34913 1/20 0.47
NR1H4 Q96RI1 1/20 0.47
IDO1 P14902 1/20 0.47
BRPF1 P55201 1/20 0.44
AURKA O14965 1/20 0.43
KDR P35968 1/20 0.43
AURKB Q96GD4 1/20 0.43
NR3C2 P08235 1/20 0.42
KIF11 P52732 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPK1 P28482 1/20 0.40
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40
XBP1 P17861 1/20 0.40
AR P10275 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18423311 0.85 HPGD (0.53) MAPTHPGDLMNAHTTSMN1; SMN2
SCHEMBL13841434 0.82 HPGD (0.50) MAPTHPGDLMNAHTTSMN1; SMN2
SCHEMBL25043309 0.81 ALDH1A1 (0.51) MAPTHPGDLMNAHTTSMN1; SMN2
SCHEMBL18423548 0.79 FKBP1A (0.56) MAPTHPGDLMNAHTTSMN1; SMN2
SCHEMBL16658371 0.78 NR1H4 (0.50) MAPTHPGDLMNAHTTSMN1; SMN2
SCHEMBL18423483 0.77 TSHR (0.55) MAPTHPGDLMNAHTTSMN1; SMN2
SCHEMBL31453567 0.77 IDO1 (0.51) MAPTLMNAEPHX2IDO1L3MBTL1
SCHEMBL2129951 0.75 HPGD (0.64) MAPTHPGDLMNAHTTSMN1; SMN2
SCHEMBL22060017 0.75 HPGD (0.46) MAPTHPGDLMNAHTTSMN1; SMN2
SCHEMBL14414960 0.75 HPGD (0.46) MAPTHPGDLMNAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150183784-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150183784-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 MAPT 2462/4885HPGD 1266/4885LMNA 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.